Latest Insider Transactions at Intellia Therapeutics, Inc. (NTLA)
This section provides a real-time view of insider transactions for Intellia Therapeutics, Inc. (NTLA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Intellia Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Intellia Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 01
2023
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,674
+35.24%
|
-
|
|
Mar 01
2023
|
John M Leonard President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
91,036
+9.59%
|
-
|
|
Mar 01
2023
|
James Basta EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
36,808
+26.81%
|
-
|
|
Mar 01
2023
|
Eliana Clark EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,673
+25.29%
|
-
|
|
Mar 01
2023
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
29,938
+38.63%
|
-
|
|
Jan 05
2023
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,330
-5.99%
|
$88,540
$38.66 P/Share
|
|
Jan 04
2023
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,508
-11.16%
|
$92,796
$37.21 P/Share
|
|
Jan 04
2023
|
Derek Hicks EVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,812
-9.48%
|
$67,044
$37.21 P/Share
|
|
Jan 04
2023
|
John M Leonard President and CEO |
SELL
Open market or private sale
|
Direct |
6,673
-0.86%
|
$246,901
$37.21 P/Share
|
|
Jan 04
2023
|
Eliana Clark EVP, Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
1,692
-10.47%
|
$62,604
$37.21 P/Share
|
|
Jan 04
2023
|
Glenn Goddard EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,427
-13.61%
|
$89,799
$37.21 P/Share
|
|
Jan 04
2023
|
David Lebwohl EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,574
-9.11%
|
$95,238
$37.21 P/Share
|
|
Jan 04
2023
|
James Basta EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
1,138
-5.5%
|
$42,106
$37.21 P/Share
|
|
Jan 03
2023
|
Eliana Clark EVP, Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
231
-1.41%
|
$7,854
$34.48 P/Share
|
|
Jan 01
2023
|
Glenn Goddard EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,062
+14.66%
|
-
|
|
Jan 01
2023
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,187
+10.13%
|
-
|
|
Jan 01
2023
|
John M Leonard President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,848
+1.0%
|
-
|
|
Jan 01
2023
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+13.48%
|
-
|
|
Jul 01
2022
|
Eliana Clark EVP, Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
105
-0.65%
|
$5,355
$51.74 P/Share
|
|
Jun 14
2022
|
Muna Bhanji |
BUY
Grant, award, or other acquisition
|
Direct |
2,014
+16.81%
|
-
|
|
Jun 14
2022
|
Fred E Cohen |
BUY
Grant, award, or other acquisition
|
Direct |
5,197
+12.23%
|
-
|
|
Jun 14
2022
|
John F Crowley Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,197
+41.62%
|
-
|
|
Jun 14
2022
|
Caroline Dorsa Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,197
+29.04%
|
-
|
|
Jun 14
2022
|
Jean Francois Formela Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,197
+41.62%
|
-
|
|
Jun 14
2022
|
Jesse Goodman |
BUY
Grant, award, or other acquisition
|
Direct |
5,197
+41.62%
|
-
|
|
Jun 14
2022
|
Georgia Keresty |
BUY
Grant, award, or other acquisition
|
Direct |
5,197
+30.72%
|
-
|
|
Jun 14
2022
|
Frank Verwiel |
BUY
Grant, award, or other acquisition
|
Direct |
5,197
+41.62%
|
-
|
|
Apr 28
2022
|
Muna Bhanji |
BUY
Grant, award, or other acquisition
|
Direct |
7,954
+50.0%
|
-
|
|
Mar 01
2022
|
Eliana Clark EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,527
+39.44%
|
-
|
|
Mar 01
2022
|
John M Leonard President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
40,990
+5.08%
|
-
|
|
Mar 01
2022
|
James Basta EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
20,697
+40.9%
|
-
|
|
Mar 01
2022
|
Glenn Goddard EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,720
+46.27%
|
-
|
|
Mar 01
2022
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,816
+35.84%
|
-
|
|
Mar 01
2022
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,816
+42.58%
|
-
|
|
Jan 03
2022
|
Derek Hicks EVP, Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,118
+50.0%
|
-
|
|
Jan 01
2022
|
John M Leonard President and CEO |
SELL
Open market or private sale
|
Direct |
2,493
-0.34%
|
$279,216
$112.25 P/Share
|
|
Jan 01
2022
|
John M Leonard President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,848
+1.07%
|
-
|
|
Jan 01
2022
|
Glenn Goddard EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,013
-33.08%
|
$113,456
$112.24 P/Share
|
|
Jan 01
2022
|
Glenn Goddard EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,062
+50.0%
|
-
|
|
Jan 01
2022
|
David Lebwohl EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,051
-8.78%
|
$117,712
$112.24 P/Share
|
|
Jan 01
2022
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,187
+21.02%
|
-
|
|
Jan 01
2022
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,148
-19.25%
|
$128,576
$112.25 P/Share
|
|
Jan 01
2022
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+36.99%
|
-
|
|
Nov 05
2021
|
David Lebwohl EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,400
-5.85%
|
$319,200
$133.44 P/Share
|
|
Nov 05
2021
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,400
+17.76%
|
$28,800
$12.62 P/Share
|
|
Oct 14
2021
|
David Lebwohl EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,400
-4.73%
|
$307,200
$128.81 P/Share
|
|
Oct 14
2021
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,400
+17.76%
|
$28,800
$12.62 P/Share
|
|
Oct 11
2021
|
John F Crowley Director |
SELL
Open market or private sale
|
Direct |
2,500
-54.42%
|
$297,500
$119.55 P/Share
|
|
Oct 11
2021
|
John F Crowley Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+35.24%
|
$45,000
$18.83 P/Share
|
|
Oct 05
2021
|
John F Crowley Director |
SELL
Open market or private sale
|
Direct |
10,000
-27.69%
|
$1,300,000
$130.84 P/Share
|